BRPI0916609A2 - Processo para a preparação de um macrociclo - Google Patents

Processo para a preparação de um macrociclo

Info

Publication number
BRPI0916609A2
BRPI0916609A2 BRPI0916609-2A BRPI0916609A BRPI0916609A2 BR PI0916609 A2 BRPI0916609 A2 BR PI0916609A2 BR PI0916609 A BRPI0916609 A BR PI0916609A BR PI0916609 A2 BRPI0916609 A2 BR PI0916609A2
Authority
BR
Brazil
Prior art keywords
macrocycle
preparation
Prior art date
Application number
BRPI0916609-2A
Other languages
English (en)
Inventor
Michelangelo Scalone
Helmut Stahr
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BRPI0916609A2 publication Critical patent/BRPI0916609A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16—Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Materials Engineering (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
BRPI0916609-2A 2008-08-07 2009-07-28 Processo para a preparação de um macrociclo BRPI0916609A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP08162026 2008-08-07
PCT/EP2009/059717 WO2010015545A1 (en) 2008-08-07 2009-07-28 Process for the preparation of a macrocycle

Publications (1)

Publication Number Publication Date
BRPI0916609A2 true BRPI0916609A2 (pt) 2015-08-04

Family

ID=41100507

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0916609-2A BRPI0916609A2 (pt) 2008-08-07 2009-07-28 Processo para a preparação de um macrociclo

Country Status (12)

Country Link
US (1) US8106187B2 (pt)
EP (1) EP2323981B1 (pt)
JP (1) JP5728752B2 (pt)
KR (1) KR101647520B1 (pt)
CN (1) CN102112442B (pt)
AU (1) AU2009278075B2 (pt)
BR (1) BRPI0916609A2 (pt)
CA (1) CA2732091A1 (pt)
ES (1) ES2461841T3 (pt)
IL (1) IL209592A (pt)
MX (1) MX2011000789A (pt)
WO (1) WO2010015545A1 (pt)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
BRPI0918868B8 (pt) 2008-09-18 2021-05-25 Naurex Inc compostos moduladores do receptor de nmda e composições compreendendo os mesmos
AR075584A1 (es) * 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
US8232246B2 (en) 2009-06-30 2012-07-31 Abbott Laboratories Anti-viral compounds
IN2012DN02693A (pt) * 2009-09-28 2015-09-04 Intermune Inc
WO2011100585A1 (en) 2010-02-11 2011-08-18 Joseph Moskal Secondary structure stabilized nmda receptor modulators and uses thereof
KR101692275B1 (ko) 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
CA2822556A1 (en) 2010-12-30 2012-07-05 Enanta Pharmaceuticals, Inc Macrocyclic hepatitis c serine protease inhibitors
EA201390988A1 (ru) 2010-12-30 2014-04-30 Энанта Фармасьютикалз, Инк. Фенантридиновые макроциклические ингибиторы сериновой протеазы вируса гепатита c
CN103502221B (zh) 2011-03-18 2016-03-30 拜耳知识产权有限责任公司 N-(3-氨甲酰基苯基)-1h-吡唑-5-甲酰胺衍生物及其用于防治动物害虫的用途
US8957203B2 (en) 2011-05-05 2015-02-17 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US10201584B1 (en) 2011-05-17 2019-02-12 Abbvie Inc. Compositions and methods for treating HCV
US8466159B2 (en) 2011-10-21 2013-06-18 Abbvie Inc. Methods for treating HCV
DE202012012955U1 (de) 2011-10-21 2014-07-14 Abbvie Inc. Eine Kombination aus mindestens zwei direkt wirkenden antiviralen Wirkstoffen (DAAs) für die Verwendung zur Behandlung von HCV
EP2583677A3 (en) 2011-10-21 2013-07-03 Abbvie Inc. Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon.
US8492386B2 (en) 2011-10-21 2013-07-23 Abbvie Inc. Methods for treating HCV
CA2848377A1 (en) 2011-10-28 2013-05-02 Janssen Pharmaceuticals, Inc. Improved process for preparing an intermediate of the macrocyclic protease inhibitor tmc 435
SG11201408648YA (en) 2012-06-29 2015-01-29 Apeiron Synthesis Sa Metal complexes, their application and methods of carrying out of metathesis reaction
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
US20140100364A1 (en) 2012-10-08 2014-04-10 Abbvie Inc. Compounds Useful For Making HCV Protease Inhibitors
EA025560B1 (ru) 2012-10-19 2017-01-30 Бристол-Майерс Сквибб Компани Ингибиторы вируса гепатита с
US9643999B2 (en) 2012-11-02 2017-05-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US9334279B2 (en) 2012-11-02 2016-05-10 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2914613B1 (en) 2012-11-02 2017-11-22 Bristol-Myers Squibb Company Hepatitis c virus inhibitors
US9409943B2 (en) 2012-11-05 2016-08-09 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
EP2951186B1 (en) 2013-01-29 2018-07-25 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20151416A1 (es) 2013-01-29 2015-10-10 Naurex Inc Moduladores de receptores nmda de espiro-lactama y sus usos
US9758525B2 (en) 2013-01-29 2017-09-12 Aptinyx Inc. Spiro-lactam NMDA receptor modulators and uses thereof
KR102410989B1 (ko) 2013-01-29 2022-06-17 앱티닉스 인크. 스피로-락탐 nmda 수용체 조절인자 및 그의 용도
JP2016506962A (ja) 2013-01-29 2016-03-07 ノーレックス, インコーポレイテッドNaurex, Inc. スピロラクタム系ｎｍｄａ受容体モジュレーターおよびその使用
JP6342922B2 (ja) 2013-03-07 2018-06-13 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ Ｃ型肝炎ウイルス阻害剤
WO2014145095A1 (en) 2013-03-15 2014-09-18 Gilead Sciences, Inc. Macrocyclic and bicyclic inhibitors of hepatitis c virus
WO2015103490A1 (en) 2014-01-03 2015-07-09 Abbvie, Inc. Solid antiviral dosage forms
EA201892448A1 (ru) 2016-04-28 2019-06-28 Эмори Юниверсити Алкинсодержащие нуклеотидные и нуклеозидные терапевтические композиции и связанные с ними способы применения
WO2017201285A1 (en) 2016-05-19 2017-11-23 Aptinyx Inc. Spiro-lactam nmda receptor modulators and uses thereof
PE20190174A1 (es) 2016-05-19 2019-02-01 Aptinyx Inc Moduladores del receptor espiro-lactama n-metil-d-aspartato y usos de los mismos
IL286107B2 (en) 2016-08-01 2024-09-01 Aptinyx Inc Spiro-lactam nmda receptor modulators and usesthereof
AU2017306158B2 (en) 2016-08-01 2021-10-14 Aptinyx Inc. Spiro-lactam and bis-spiro-lactam NMDA receptor modulators and uses thereof
JP7036792B2 (ja) 2016-08-01 2022-03-15 アプティニックス インコーポレイテッド スピロ－ラクタムｎｍｄａ受容体修飾因子およびその使用
WO2018026798A1 (en) 2016-08-01 2018-02-08 Aptinyx Inc. Spiro-lactam nmda modulators and methods of using same
KR102465758B1 (ko) 2016-08-01 2022-11-09 앱티닉스 인크. 스피로-락탐 nmda 수용체 조정제 및 그의 용도
PE20210455A1 (es) 2018-01-31 2021-03-08 Aptinyx Inc Moduladores del receptor nmda espiro-lactama y usos de los mismos
US12012413B2 (en) 2019-11-11 2024-06-18 Tenacia Biotechnology (Hong Kong) Co., Limited Methods of treating painful diabetic peripheral neuropathy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5831108A (en) * 1995-08-03 1998-11-03 California Institute Of Technology High metathesis activity ruthenium and osmium metal carbene complexes
WO2005037214A2 (en) * 2003-10-14 2005-04-28 Intermune, Inc. Macrocyclic carboxylic acids and acylsulfonamides as inhibitors of hcv replication
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
AP2006003763A0 (en) * 2004-03-30 2006-10-31 Intermune Inc Macrocyclic compounds as inhibitors of viral replication
MX2008001166A (es) * 2005-07-25 2008-03-18 Intermune Inc Nuevos inhibidores macrociclicos de la replicacion del virus de hepatitis c.
EP1934243B1 (en) 2005-09-09 2011-05-25 Boehringer Ingelheim International GmbH Ring-closing metathesis process for the preparation of macrocyclic peptides
EP2111227A1 (en) * 2007-01-08 2009-10-28 Phenomix Corporation Macrocyclic hepatitis c protease inhibitors
WO2009070692A1 (en) * 2007-11-29 2009-06-04 Enanta Pharmaceuticals, Inc. C5-substituted, proline-derived, macrocyclic hepatitis c serine protease inhibitors
CA2709032C (en) * 2007-12-21 2016-02-23 F. Hoffmann-La Roche Ag Process for the preparation of a macrocycle
WO2009137432A1 (en) * 2008-05-09 2009-11-12 Boehringer Ingelheim International Gmbh A method for preparing macrocycles

Also Published As

Publication number Publication date
JP2011529935A (ja) 2011-12-15
EP2323981A1 (en) 2011-05-25
KR20110053422A (ko) 2011-05-23
IL209592A0 (en) 2011-01-31
AU2009278075A1 (en) 2010-02-11
US8106187B2 (en) 2012-01-31
CA2732091A1 (en) 2010-02-11
ES2461841T3 (es) 2014-05-21
KR101647520B1 (ko) 2016-08-10
EP2323981B1 (en) 2014-03-12
CN102112442B (zh) 2014-12-10
CN102112442A (zh) 2011-06-29
JP5728752B2 (ja) 2015-06-03
WO2010015545A1 (en) 2010-02-11
IL209592A (en) 2014-07-31
MX2011000789A (es) 2011-02-24
US20100036116A1 (en) 2010-02-11
AU2009278075B2 (en) 2013-07-04

Similar Documents

Publication Publication Date Title
BRPI0916609A2 (pt) Processo para a preparação de um macrociclo
BRPI0911254A2 (pt) processo para a preparação de um composto
BRPI0820733A2 (pt) Processo para a preparação de macrociclo
BRPI1013561A2 (pt) Processo para a preparação de alogliptina
BRPI0910916A2 (pt) Processo para a produção de um dianidroaçúcar
BRPI0920356A2 (pt) Processo para a preparação de compostos úteis como inibidores de sglt
BRPI0816258A2 (pt) processo para a preparação de compostos úteis como inibidores de sglt
BRPI0923748A2 (pt) Método para a preparação de dióis
PT2121578T (pt) Processo de preparação de ácido 5-bifenil-4-amino-2-metil-pentanoico
BR112012014490A2 (pt) processo para a preparação substituída de 1-o-acil-2-desóxi-2-fluoro-4-tio-beta-d-arabinofuranoses
BRPI0909393A2 (pt) processo para a preparação de polibutadieno
BRPI0812422A2 (pt) Processo de preparação de um aldeído hidroxiaromático
BRPI0915572A2 (pt) processo para a fabricação de epicloroidrina
BRPI0816911A2 (pt) Processo para preparação de 4-aminobut-2-enolidas
BRPI0908252A2 (pt) Processo para preparar um composto, e, uso de um composto
BRPI0817747A2 (pt) Processo para a preparação de derivados de ácido 2-di-halogenoacil-3-amino-acrílico
BRPI0911897A2 (pt) Processo para a preparação de compostos, e, composto
BRPI0914674A2 (pt) processo para preparação de um pó
BRPI1010933A2 (pt) processo para a preparação de um pó, e, composto
BRPI0815784A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0921420A2 (pt) processo para preparar compostos
BRPI0815971A2 (pt) Processo para a preparação de 1,2-propanodiol
BRPI0813788A2 (pt) Processo para preparação de metacrilato de alila
BRPI0913989A2 (pt) processo para preparação de derivados de benzoimidazol-2-il pirirmidina
BRPI0911992A2 (pt) processo para preparação de bifenilanilidas substituídas

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2472 DE 22-05-2018 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.